INT J LAB HEMATOL:凝血酶原时间和凝块波形分析在检测肝硬化出血风险方面有用吗?

2019-01-27 MedSci MedSci原创

目前认为凝血酶原时间在肝硬化患者预测出血的风险是不可靠的。本研究在对凝血酶原时间比进行血栓波形分析的同时,研究了凝血酶原时间比是否是出血的独立危险因素。 研究人员纳入307名肝硬化患者和115名健康受试者。采用凝血仪检测凝血酶原时间和凝块波形分析,包括凝块形成的速度(一阶导数)和加速度(二阶导数),以及凝血酶原时间一阶导数和二阶导数抛物线段面积(凝块形成的整个周期)。 Logistic

目前认为凝血酶原时间在肝硬化患者预测出血的风险是不可靠的。本研究在对凝血酶原时间比进行血栓波形分析的同时,研究了凝血酶原时间比是否是出血的独立危险因素。

研究人员纳入307名肝硬化患者和115名健康受试者。采用凝血仪检测凝血酶原时间和凝块波形分析,包括凝块形成的速度(一阶导数)和加速度(二阶导数),以及凝血酶原时间一阶导数和二阶导数抛物线段面积(凝块形成的整个周期)

Logistic回归显示凝血酶原时间比是唯一与出血史显著相关的变量。采用出血性评分法,逐步建立凝血酶原时间比和凝血酶原时间一阶导数抛物线段面积的模型。在ROC分析中,优势比被用来创建一个新的分数,与出血分数进行比较。AUC0.72,95% CI: 0.670.77

研究表明,凝血酶原时间比与出血风险增加有关。考虑到血凝块的波形分析,需要进一步强调其作用。如果将新的评分汇总为凝血酶原时间比,可为评估肝硬化患者的出血风险提供一个立即可用的单一参数。

原始出处:

Maria F. Ruberto Francesco Marongiu Orazio Sorbello Alberto Civolani Luigi Demelia Doris Barcellona, Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis?

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=359517, encodeId=4fa235951e21, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Tue Jan 29 13:39:46 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317465, encodeId=5f9b131e46530, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Jan 29 07:51:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415958, encodeId=57781415958c4, content=<a href='/topic/show?id=6e0631341b6' target=_blank style='color:#2F92EE;'>#凝血酶原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31341, encryptionId=6e0631341b6, topicName=凝血酶原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15d23117049, createdName=gostraight, createdTime=Tue Jan 29 07:51:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046370, encodeId=75ca10463e0b8, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Sun Jan 27 19:51:00 CST 2019, time=2019-01-27, status=1, ipAttribution=)]
    2019-01-29 衣带渐宽

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=359517, encodeId=4fa235951e21, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Tue Jan 29 13:39:46 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317465, encodeId=5f9b131e46530, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Jan 29 07:51:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415958, encodeId=57781415958c4, content=<a href='/topic/show?id=6e0631341b6' target=_blank style='color:#2F92EE;'>#凝血酶原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31341, encryptionId=6e0631341b6, topicName=凝血酶原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15d23117049, createdName=gostraight, createdTime=Tue Jan 29 07:51:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046370, encodeId=75ca10463e0b8, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Sun Jan 27 19:51:00 CST 2019, time=2019-01-27, status=1, ipAttribution=)]
    2019-01-29 fengyi812
  3. [GetPortalCommentsPageByObjectIdResponse(id=359517, encodeId=4fa235951e21, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Tue Jan 29 13:39:46 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317465, encodeId=5f9b131e46530, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Jan 29 07:51:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415958, encodeId=57781415958c4, content=<a href='/topic/show?id=6e0631341b6' target=_blank style='color:#2F92EE;'>#凝血酶原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31341, encryptionId=6e0631341b6, topicName=凝血酶原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15d23117049, createdName=gostraight, createdTime=Tue Jan 29 07:51:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046370, encodeId=75ca10463e0b8, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Sun Jan 27 19:51:00 CST 2019, time=2019-01-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=359517, encodeId=4fa235951e21, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Tue Jan 29 13:39:46 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317465, encodeId=5f9b131e46530, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Jan 29 07:51:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415958, encodeId=57781415958c4, content=<a href='/topic/show?id=6e0631341b6' target=_blank style='color:#2F92EE;'>#凝血酶原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31341, encryptionId=6e0631341b6, topicName=凝血酶原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15d23117049, createdName=gostraight, createdTime=Tue Jan 29 07:51:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046370, encodeId=75ca10463e0b8, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Sun Jan 27 19:51:00 CST 2019, time=2019-01-27, status=1, ipAttribution=)]
    2019-01-27 guging

    谢谢!最新的信息读起来就是收获大

    0

相关资讯

JAMA Surg:肝癌患者术后晚期复发的影响因素研究

研究认为肝癌切除术后的晚期复发与性别、肝硬化和原发性肝癌的多个侵袭性肿瘤特征有关,积极的术后监测有助于提高晚期复发人群的生存率

J Hepatol:酒精性肝硬化 预防骨折性命攸关

肝硬化的患病率正在不断增加,其是骨质疏松和骨折的风险因素。肝硬化后骨折对生命构成极大的威胁,甚至估计30天死亡率高达10%。但目前对酒精性肝硬化患者髋部骨折的实际风险知之甚少。

J Periodontol: 肝移植患者牙周状况的研究

本研究旨在比较肝移植候选者(LTCs)与健康对照的牙周状况。

肝硬化20余年,2天揭开其神秘面纱

1. 患者杜某,女,56岁,以 “反复腹胀伴双下肢水肿20余年,上腹痛3周”为主诉于2019年1月6日入院。

Gastroenterology:肝硬化人群耐药菌感染风险评估

研究发现,肝硬化患者耐药菌感染风险增加,特别是印度患者的耐药菌感染率最高

肝硬化患者的治疗:抗病毒还是抗纤维化?

多年乙肝小三阳患者,男,44岁。近期B超检查发现肝硬化轻度,为此做了两次HBV_DNA定量检测:第一次:HBV_DNA<500IU/ml;第二次:采用ROCHE定量试剂,测得值为2.66*10^3IU/ml。